Early recurrences of atrial fibrillation after electrical cardioversion: A results of fibrillation-induced electrical remodeling of the atria?

Journal of the American College of Cardiology

Volumn 31, Issue 1, 1998, Pages 167-173

  Tieleman, Robert G ^a   Van Gelder, Isabelle C ^a   Crijns, Harry J G M ^a   De Kam, Pieter J ^a   Van Den Berg, Maarten P ^a   Haaksma, Jaap ^a   Van Der Woude, Hanneke J ^a   Allessie, Maurits A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; FLECAINIDE; PROPAFENONE; SOTALOL;

ADULT; AGED; ARTICLE; CALCIUM CELL LEVEL; CARDIOVERSION; FEMALE; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SUPRAVENTRICULAR PREMATURE BEAT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; ELECTRIC COUNTERSHOCK; FEMALE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE;

EID: 0031932414     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00455-5     Document Type: Article

References (51)

1. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation a controlled clinical study . Br Heart J. 33:1971;518-521.
2. Edhag O, Erhardt LR, Lundman T, Södermark T, Sjögren A. Verapamil and quinidine in maintaining sinus rhythm after electroconversion of atrial fibrillation. Opusc Med. 27:1982;22-24.
3. Karlson BW, Torstensson I, Åbjörn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electrocardioversion of atrial fibrillation a placebo controlled one-year follow-up study . Eur Heart J. 9:1988;284-290.
4. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 12:1988;1005-1011.
5. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 64:1989;1317-1321.
6. Juul-Möller S, Edvardsson N, Rehnquist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:1990;1932-1939.
7. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 68:1991;41-46.
8. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 71:1993;558-563.
9. Crijns HJGM, Gosselink ATM, Lie KI, for the PRODIS study group. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. Cardiovasc Drugs Ther 1996;10:145-52.
10. Wijffels MCEF, Kirchof CJHJ, Dorland R, Allessie MA. AF begets AF a study in awake chronically instrumented goats . Circulation. 92:1995;1954-1968.
11. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid atrial pacing structural, functional and electrophysiologic characteristics of a new model of sustained AF . Circulation. 91:1995;1588-1595.
12. Goette A, Honeycutt G, Langberg JJ. Electrical remodeling in atrial fibrillation time course and mechanisms . Circulation. 94:1996;2968-2974.
13. Tieleman RG, De Langen CDJ, Van Gelder IC, et al. Verapamil reduces tachycardia induced electrical remodeling of the atria. Circulation. 95:1997;1945-1953.
14. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil on atrial fibrillation-induced electrical remodeling [abstract]. Circulation. 94:(Suppl I):1996;I-30.
15. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink ATM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic AF or atrial flutter. Am J Cardiol. 68:1991;335-341.
16. Allessie MA, Lamers WJEP, Smeets JRLM, Bonke FIM, Hollen SJ. Total mapping of atrial excitation during acetylcholine-induced atrial flutter and fibrillation in the isolated canine heart. Kulbertus HE, Olsson SB, Schlepper M. Atrial Fibrillation. 1982;44-62 Lindgren and Soner, Molndal, Sweden.
17. Allessie MA, Lamers WJEP, Bonke FIM, Hollen SJ. Experimental evaluation of Moe's multiple wavelet hypothesis of AF. Zipes DP, Jalife J. Cardiac Electrophysiology and Arrhythmias. 1985;265-275 Grune and Stratton, New York.
18. Cox JL, Canavan TE, Schuessler RB, et al. The surgical treatment of atrial fibrillation. II Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation . J Thorac Cardiovasc Surg. 101:1991;406-426.
19. Wang Z, Page PL, Nattel S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 71:1992;271-287.
20. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation importance of use dependent effects on refractoriness . Circulation. 88:1993;1030-1044.
21. Kirchhof CJHJ, Chorro F, Scheffer GJ, et al. Regional entrainment of atrial fibrillation studied by high-resolution mapping in open-chest dogs. Circulation. 88:1993;736-749.
22. Konings KTS, Kirchhof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA. High density mapping of electrically induced atrial fibrillation in man. Circulation. 89:1994;1665-1680.
23. Holm M, Blomstrom P, Brandt J, Johansson R, Luhrs C, Olsson SB. Determination of preferable directions of impulse propagation during atrial fibrillation by time averaging of multiple electrogram vectors. Olsson SB, Allessie MA, Campbell RWF. Atrial Fibrillation - Mechanisms and Therapeutic Strategies. 1994;67-80 Futura, Armonk (NY).
24. Moe GK, Abildskov JA. AF as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 58:1959;59-70.
25. Moe GK. On the multiple wavelet hypothesis of AF. Arch Int Pharmacodyn Ther. 140:1962;183-188.
26. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of AF. Am Heart J. 67:1964;200-220.
27. Lewis T. The Mechanism and Graphic Registration of the Heart Beat. 1925;Shaw and Sons, London.
28. Wiener N, Rosenblueth A. The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, especially in cardiac muscle. Arch Inst Cardiol Mex. 16:1946;205-265.
29. Smeets JLRM, Allessie MA, Lammers WJEP, Bonke FIM, Hollen SJ. The wavelength of the cardiac impulse and reentrant arrhythmias in isolated rabbit atrium the role of heart rate, autonomic transmitters, temperature and potassium . Circ Res. 58:1986;96-108.
30. Rensma PL, Allessie MA, Lamers WJEP, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in conscious dogs. Circ Res. 62:1988;395-410.
31. Olsson SB, Cotoi S, Varnauskas E. Monophasic action potential and sinus rhythm stability after conversion of AF. Acta Med Scand. 190:1971;381-387.
32. Cotoi S, Gavrilescu S, Pop T, Vicas E. The prognostic value of right atrium monophasic action potential after conversion of AF. Eur J Clin Invest. 2:1972;472-474.
33. Attuel P, Childers RW, Cauchemez B, Poveda J, Mugica J, Coumel P. Failure in rate adaptation of the atrial refractory period its relation to vulnerability . Int J Cardiol. 2:1982;179-197.
34. Attuel P, Childers RW, Haissaguerre M, Lecercq J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory periods new parameter to assess atrial vulnerability . PACE. 7:1984;1382.
35. Le Heuzey J, Boutjdir M, Gagey S, Lavergne T, Guize L. Cellular aspects of atrial vulnerability. Attuel P, Olsson SB, Schlepper M. The Atrium in Health and Disease. 1989;81-94 Futura, Mount Kisco (NY).
36. Franz MR, Cuilan L, Karasik P, Fletcher RD. Abnormal action potential duration/cycle length relation in patients cardioverted from atrial fibrillation [abstract]. Circulation. 92:(Suppl I):1995;I-404.
37. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation of atrial refractoriness in humans. Circulation. 94:1996;1600-1606.
38. Van Gelder IC, Crijns HJGM, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 72:1993;560-566.
39. Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial function after cardioversion relation to the duration of atrial fibrillation . J Am Coll Cardiol. 23:1994;1535-1540.
40. Rinkenberger RL, Prystowsky EN, Heger JJ, Troup PJ, Jackman WM, Zipes DP. Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation. 62:1980;996-1010.
41. Waxman HL, Meyerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and AF or flutter. Ann Intern Med. 94:1981;1-6.
42. Singh BN, Nademanee K. Use of calcium antagonists for cardiac arrhythmias. Am J Cardiol. 59:1987;153B-162B.
43. Plumb VJ, Karf RB, Kouchoukas NT, Zorn GL Jr, James TN, Waldo AL. Verapamil therapy of AF and atrial flutter following cardiac operation. J Thorac Cardiovasc Surg. 83:1982;590-596.
44. Tommaso C, McDonough T, Parker M, Tabano JV. AF and flutter immediate control and conversion with intravenously administered verapamil . Arch Intern Med. 143:1983;877-881.
45. Ochs HR, Anda L, Eichlbaum M, Greenblatt DJ. Diltiazem, verapamil and quinidine in patients with chronic AF. Clin Pharmacol. 25:1985;204-209.
46. Hillestad L, Andersen A. Beta-receptor blockade in maintenance of sinus rhythm obtained by electroconversion. Acta Med Scand. 185:1996;535-538.
47. Crozier IG, Ikram H, Kenealy M, Levy L. Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am J Cardiol. 59:1987;607-609.
48. Crijns HJGM, Van Wijk LM, Van Gilst WH, Kingma JH, Van Gelder IC, Lie KI. Acute conversion of AF to sinus rhythm clinical efficacy of flecainide acetate. Comparison of two regimens . Eur Heart J. 9:1988;634-638.
49. Suttorp MJ, Kingma HJ, Lie-A-Huen L, Mast GE. Intravenous flecainide versus verapamil for acute conversion of paroxysmal AF or flutter to sinus rhythm. Am J Cardiol. 63:1989;693-696.
50. Suttorp MJ, Kingma HJ, Jessurun ER, Lie-A-Huen L, Van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal AF or flutter to sinus rhythm. J Am Coll Cardiol. 16:1990;1722-1727.
51. Tieleman RG, Gosselink ATM, Crijns HJGM, et al. Efficacy, safety, and determinants of conversion of AF and flutter on oral amiodarone. Am J Cardiol. 79:1997;53-57.